AbbVie Inc. $ABBV Shares Sold by Capital World Investors

Capital World Investors lowered its stake in AbbVie Inc. (NYSE:ABBV) by 2.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,335,283 shares of the company’s stock after selling 139,297 shares during the period. Capital World Investors’ holdings in AbbVie were worth $1,466,782,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of ABBV. Brighton Jones LLC increased its holdings in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after purchasing an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC boosted its holdings in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. raised its stake in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after purchasing an additional 789 shares during the last quarter. Penserra Capital Management LLC lifted its stake in shares of AbbVie by 500.0% in the second quarter. Penserra Capital Management LLC now owns 864 shares of the company’s stock worth $159,000 after buying an additional 720 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in shares of AbbVie during the 2nd quarter worth approximately $581,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie reported positive topline results from the Phase 1 multiple ascending dose study of ABBV-295 (long‑acting amylin analog) showing roughly 7.8–9.8% mean weight loss at ~12 weeks and a favorable tolerability profile — supports further development in chronic weight management and expands non‑incretin obesity options. AbbVie reports topline data from Phase I ABBV-295 trial
• Positive Sentiment: AbbVie announced positive Phase 3 AFFIRM results for SKYRIZI (risankizumab) subcutaneous induction in Crohn’s disease — a potential label/indication expansion that could extend revenue runway for an existing franchise. AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study
• Positive Sentiment: Industry coverage highlights ABBV‑295 and early obesity program data (up to ~10% weight loss) as a differentiator vs. incretin therapies — this boosts perception of AbbVie’s cardiometabolic pipeline optionality. AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study
• Positive Sentiment: J.P. Morgan reiterated its Buy stance on ABBV, an institutional vote of confidence that can support demand for the shares. J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
• Neutral Sentiment: Citi’s Geoff Meacham maintained a Hold and $230 price target, signaling caution despite pipeline promise and limiting upside from analyst revisions. Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors
• Neutral Sentiment: ResearchAndMarkets published an Elahere (mirvetuximab) market report outlining growth drivers in ovarian cancer — useful long‑term market context but not an immediate mover for ABBV shares. Elahere (AbbVie: mirvetuximab soravtansine-gynx) Market Research Report 2026
• Neutral Sentiment: AbbVie’s presentation/transcript at the Leerink Global Healthcare Conference provides management insight on growth drivers and pipeline prioritization — useful for modeling but not an immediate catalyst. AbbVie Inc. (ABBV) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: ICER (cost‑effectiveness body) will review AbbVie’s Parkinson’s drug — an adverse assessment could limit pricing power/reimbursement and pressure long‑term revenue assumptions. ICER to review AbbVie’s Parkinson’s disease drug
• Negative Sentiment: Governance/headline risks: CEO Robert Michael received a sizable pay increase to $32.5M in year two, and an AbbVie SVP sold ~$1.22M in shares — both items can weigh on sentiment among governance‑focused investors. AbbVie’s Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO AbbVie (NYSE:ABBV) SVP Sells $1,221,518.80 in Stock

AbbVie Stock Performance

ABBV stock opened at $226.68 on Wednesday. The stock has a market capitalization of $400.81 billion, a PE ratio of 96.05, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34. The company has a fifty day moving average of $224.60 and a 200-day moving average of $224.45. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the business posted $2.16 EPS. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is presently 293.22%.

Insider Transactions at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.08% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ABBV. Evercore cut their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a report on Wednesday, February 4th. Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 28th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday, February 5th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. Finally, Piper Sandler raised their price objective on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.